Bioventus Announces Pricing of Initial Public Offering
DURHAM, N.C., Feb. 10, 2021 - Bioventus has priced its initial public offering (IPO) of 8,000,000 shares of Class A common stock at $13.00 per share. The shares are expected to begin trading on Nasdaq under the symbol 'BVS', with the offering set to close on February 16, 2021. The gross proceeds from the offering are anticipated to be around $104 million, potentially increasing to $119.6 million if underwriters exercise their option for an additional 1,200,000 shares. Morgan Stanley, J.P. Morgan, and Goldman Sachs are the lead underwriters.
- Initial public offering priced at $13.00 per share.
- Gross proceeds expected to be approximately $104 million, increasing to $119.6 million if the underwriters fully exercise their option.
- Potential for shareholder dilution from the additional shares if the underwriters exercise their option.
DURHAM, N.C., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. ("Bioventus" or the “Company”) today announced the pricing of its initial public offering of 8,000,000 shares of Class A common stock at a public offering price of
The underwriters have also been granted a 30-day option to purchase up to 1,200,000 additional shares of Class A common stock from Bioventus at the initial public offering price, less underwriting discounts and commissions.
The gross proceeds to the Company from the offering, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be approximately
Morgan Stanley, J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are serving as joint lead book-running managers and as representatives of the underwriters for the proposed offering. Canaccord Genuity LLC is acting as lead manager for the offering.
The offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the proposed offering may be obtained from any of the following sources:
- Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com;
- J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 1-866-803-9204 or by email at prospectus-eq_fi@jpmchase.com; or
- Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com.
A registration statement relating to these securities has been declared effective by the Securities and Exchange Commission ("SEC") on February 10, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide.
SOURCE: Bioventus Inc.
Contacts:
Investors
Bioventus Investor Relations
Investor.relations@bioventus.com
Media
Thomas Hill
thomas.hill@bioventusglobal.com
FAQ
What is Bioventus' IPO price and share count?
When will Bioventus begin trading on Nasdaq?
How much money is Bioventus aiming to raise from the IPO?
Who are the underwriters for Bioventus' IPO?
